SGLT-2 Therapy Center

First results from phase 3 CANVAS trial show canagliflozin as add-on therapy to insulin lowered blood sugar levels in patients with type 2 diabetes at an elevated risk for cardiovascular disease…. Canagliflozin was also shown to be effective and generally well-tolerated in patients with type 2 diabetes aged 55 to …

Empagliflozin reduced HbA1c, fasting plasma glucose and body weight when administered alone or as an add-on to metformin in patients with type 2 diabetes….  Adults with type 2 diabetes who had participated in one of two 12-week studies of empagliflozin (Boehringer Ingelheim, Eli Lilly) were treated for an additional 78 …

History of the sodium-glucose co-transporter (SGLT) inhibitors by Erica Paul, PharmD, Graduate Intern University of Florida College of Pharmacy Back in the late 1800’s, a compound called phlorizin, found in the bark of apple trees, was isolated by French chemists. Since then it has been put to use in multiple …

The ACP has issued a clinical practice guideline regarding use of oral agents in type 2 diabetes entitled, “Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline From the American College of Physicians.”… This is important because despite new therapies, there hasn’t been a guideline from either …

Diabetes In Control Publisher Steve Freed interviewed Dr. David D’Alessio, Associate Professor of Medicine, Division of Endocrinology, University of Cincinnati, and the Albert Vontz chair in Diabetes Research. Dr. D’Alessio helps us understand some of the newest research on GLP-1’s, how he uses these therapies in his own practice and …

The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 9 to 6 against recommending the approval of the first in class novel antidiabetic agent dapagliflozin, largely because of fears that the product may cause breast and bladder cancer.… The EMDAC panel was also concerned about a lack of pharmacokinetic …

Three possible first in class drugs in the sodium glucose co-transporter (SGLT2 inhibitor) class showed improvements in glycemic control and weight loss, but infections proved troublesome, researchers reported…. Michael Nauck, MD, and colleagues of Diabeteszentrum Bad Lauterberg in Harz, Germany, looked at studies involving three investigational drugs in the sodium …

Inhibitors Of The Novel Target Sodium-dependent Glucose (co-) Transporter (SGLT) For Therapy Of Type 2 Diabetes A plethora of SGLT inhibitors in the patent literature and seven compounds in early clinical development indicate an abundance of interest in the therapeutic use of SGLT inhibitors for the treatment of type 2 …